Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REGEN-016 phase 3 study of REACT in type 2 diabetes mellitus and chronic kidney disease
2022-000289-16Phase 3Completed
- Sponsor
- ProKidney
- Start
- Oct 2022
- Modality
- Autologous CAR-T → CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Patient-derived iPSCs → iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of rilparencel in chronic kidney disease (CKD) and type 2 diabetes mellitus (T2DM) (2 arms), sponsored by ProKidney. Primary endpoint: Time from first injection to earliest event. Started Oct 2022; status: completed.
02
Drugs
rilparencel
03
Conditions
chronic kidney disease (CKD)type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2022-000289-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000289-16.